Roche Updates SKYSCRAPER-01 Trial: Tiragolumab and Tecentriq Combination Falls Short on Overall Survival in NSCLC

Roche has shared an update on its Phase III SKYSCRAPER-01 trial, which evaluates the combination of tiragolumab and Tecentriq® (atezolizumab) against Tecentriq alone in patients with PD-L1-high, locally advanced, or metastatic non-small cell lung cancer (NSCLC). The trial involved 534 participants who had not previously received treatment for their condition. Patients were randomly assigned to receive either the tiragolumab-Tecentriq combination or a placebo with Tecentriq until disease progression or the emergence of intolerable side effects.

The study's primary objective, overall survival, was not met during the final analysis. Despite this, the safety profile remained consistent over the extended follow-up period, and no new safety concerns were identified. Roche plans to share a comprehensive overview of the trial’s findings at a medical conference in 2025, providing further insight into the outcomes and implications of the study.

As part of its ongoing commitment to optimising its clinical research, Roche is carefully evaluating the SKYSCRAPER-01 program. The company aims to integrate data from this trial with upcoming results from other Phase III studies exploring tiragolumab in different cancer types and settings. Additional updates are expected next year as Roche continues to refine its strategy for developing innovative cancer therapies.